Amoxicillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Amoxicillin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Amoxicillin is a beta-lactam antibiotic, widely marketed in South Africa for bacterial infections. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but there are 0 clinical trials and 0 publications supporting this prediction. It is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (general antibacterial use; the SAHPRA indication text was not supplied in the data) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 14 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Amoxicillin is a beta-lactam antibacterial that acts on bacterial cell wall synthesis. Its efficacy in bacterial infections is well established.
Polyclonal hyperviscosity syndrome is a state of raised serum viscosity, not a bacterial disease. No plausible antibacterial mechanism links amoxicillin to it. The high score (0.996) reflects the model’s knowledge-graph patterns and is not supported by any trial or publication. It should not be read as a pharmacological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Amoxicillin is registered in several forms: suspension, capsule, tablet, injection and drops. The five main registrations are listed below. The approved indication text was not provided in the data.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| 36/20.1.2/0115 | Zaloxy | Suspension |
| Z/20.1.2/327 | Spectramox C 250 | Capsule |
| J/20.1.2/0437 | Suprapen 500 | Capsule |
| 41/20.1.2/0532 | Bindoclav | Tablet |
| 34/20.1.2/0251 | Ranclav | Suspension |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, no literature and no mechanistic basis. Polyclonal hyperviscosity syndrome is not a bacterial condition. The score is best treated as a knowledge-graph artefact rather than a repurposing signal.
To proceed, the following is needed:
- Amoxicillin’s mechanism of action data, and the SAHPRA package insert warnings and contraindications.
- Any credible human evidence linking amoxicillin to hyperviscosity states. None was found.
- Consideration of a better-supported prediction from the same drug: epiglottitis (rank 10, L4, stage S1). It has a strong mechanistic fit, because the likely pathogens are beta-lactam-susceptible. Support is limited to reviews, guidelines and case reports, with no RCT. Airway-threatening cases usually need parenteral third-generation cephalosporins, so a guideline and label check is the reasonable next step.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.